Amino-01 (July 2018)

Amino-01 (JULY 2018) 180124 AA SPIFAN SLV Appendices A-I

FOR ERP USE ONLY DO NOT DISTRIBUTE

Single Laboratory Validation Report for Total Amino Acids by UHPLC-UV in Infant Formulas and Adult Nutritionals -– APPENDICES (A to I) Appendix F : intermediate reproducibility data obtained with the SPIFAN II SLV kit products, color-coded with respect to reproducibility requirement values.

SPIFAN II SLV kit product

Analyte 1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 5.6% 7.6% 6.4% 3.7% 6.3% 12.0% 7.5% 4.3% 7.5% 9.3%

His

4.9% 7.8% 4.6% 11.0% 6.8% 4.7% 7.5% 7.6%

9.2%

Tau N/A N/A N/A N/A N/A

2.3% 4.2% 4.2% 10.2% 2.2%

N/A

6.3% 7.1% 3.7% 7.7% 6.6% 6.2% 3.9% 4.4%

Ser Arg

7.4% 10.6% 6.9% 5.7%

5.8%

9.0% 4.2% 5.3% 2.3% 2.4% 3.5% 7.4% 6.3% 3.0% 5.0% 7.9% 5.3%

8.8% 9.7% 6.6% 7.2%

3.7% 2.1% 2.0%

7.9%

7.6% 2.7% 6.4% 3.0%

8.1%

6.4% 5.1%

8.2%

4.3% 6.4% 8.0%

8.1%

2.0%

Gly 3.0% 3.9% 2.6% 5.5% 2.5% 1.0% 1.9% 3.1% 4.3% 5.0% 5.0% 7.2% 6.4% 3.7% 4.1% 9.4% Asp 2.0% 3.4% 1.7% 2.1% 4.2% 3.3% 4.2% 3.2% 4.3% 3.3% 1.1% 4.3% 2.3% 1.2% 6.8% 5.2% Glu 1.4% 3.7% 1.7% 2.0% 3.2% 1.2% 3.8% 2.3% 3.0% 2.9% 2.2% 4.4% 3.5% 3.2% 5.6% 5.1%

0.0% 6.2% 6.0% 3.9% 1.8% 3.8% 3.1% 1.5% 4.5%

Intermediate reproducibility data were obtained with robust statistics. For each analyte/matrix pair, the intermediate reproducibility was compared with the corresponding reproducibility requirement*. 91% of the values are within the requirements (green) and 7% outside (red). 2% could not be attributed (blank values for taurine). * updated version proposed by the amino acid working group to be reviewed by the stakeholder panel during the August 2018 annual meeting. Thr 3.1% 2.1% 2.6% 3.9% 3.1% 2.7% 1.3% 1.6% 3.6% 1.9% 0.8% 4.8% 2.8% 0.9% 2.6% 5.4% 2.5% 4.9% 5.1% Ala 2.0% 1.3% 3.5% 3.4% 3.7% 1.3% 4.3% 3.4% 3.5% 2.7% 1.9% 5.3% 4.0% 2.3% 4.6% 4.5% 2.5% 4.2% 5.6% Pro 0.6% 2.8% 1.8% 2.4% 1.9% 1.1% 1.4% 2.1% 4.2% 3.2% 3.0% 4.0% 2.3% 2.7% 3.8% 5.5% 2.1% 4.6% 5.3% Lys 1.4% 3.2% 1.6% 2.8% 3.5% 3.0% 7.4% 7.6% 2.3% 3.9% 3.9% 3.4% 3.9% 4.9% 11.3% 8.9% 6.2% 5.1% 3.1% Tyr 4.3% 5.5% 2.5% 6.2% 3.8% 2.9% 5.2% 5.6% 5.8% 2.5% 6.1% 4.3% 3.7% 1.8% 7.1% 9.2% 4.4% 4.9% 7.4% xCys 4.2% 10.6% 5.1% 3.8% 5.1% 3.4% 3.9% 5.2% 6.5% 2.4% 3.4% 3.5% 10.5% 3.7% 8.1% 8.1% 5.2% 2.6% 6.1% Met 5.7% 3.4% 1.4% 9.1% 7.7% 2.3% 2.1% 4.1% 4.1% 1.9% 1.8% 1.4% 3.3% 2.5% 4.0% 6.3% 1.9% 6.8% 7.2% Val 10.0% 0.8% 9.4% 5.5% 13.3% 6.7% 9.4% 13.8% 13.9% 7.4% 4.3% 11.9% 2.5% 6.1% 12.8% 15.0% 6.5% 11.4% 12.2% Ile 10.2% 0.5% 9.6% 8.3% 15.7% 8.6% 10.8% 12.6% 14.5% 8.8% 7.9% 13.7% 3.5% 8.0% 13.7% 14.1% 6.2% 11.8% 12.1% Leu 1.8% 3.7% 2.4% 2.3% 1.8% 1.3% 2.7% 2.6% 5.2% 4.4% 3.4% 0.9% 3.1% 2.3% 6.2% 7.9% 1.8% 4.3% 7.5% Phe 5.5% 5.2% 4.0% 5.2% 3.3% 2.5% 8.3% 6.4% 5.5% 6.1% 5.2% 5.5% 5.8% 4.4% 9.4% 8.5% 3.3% 3.7% 5.8%

Jaudzems, Guthrie, Lahrichi, and Fuerer – January 2018

page 6/22